about
NAD⁺-Metabolizing Ectoenzymes in Remodeling Tumor-Host Interactions: The Human Myeloma ModelMechanism of Action of Bortezomib and the New Proteasome Inhibitors on Myeloma Cells and the Bone Microenvironment: Impact on Myeloma-Induced Alterations of Bone RemodelingIL21R expressing CD14+CD16+ monocytes expand in multiple myeloma patients leading to increased osteoclasts.Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.The osteoblastic niche in the context of multiple myeloma.Bone marrow monocyte-/macrophage-derived activin A mediates the osteoclastogenic effect of IL-3 in multiple myeloma.Galectin-1 suppression delineates a new strategy to inhibit myeloma-induced angiogenesis and tumoral growth in vivo.Dependence on glutamine uptake and glutamine addiction characterize myeloma cells: a new attractive target.The Proteasome Inhibitor Bortezomib Maintains Osteocyte Viability in Multiple Myeloma Patients by Reducing Both Apoptosis and Autophagy: A New Function for Proteasome Inhibitors.Hypoxia-inducible factor (HIF)-1α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction.Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules.HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients.Osteolytic lesions, cytogenetic features and bone marrow levels of cytokines and chemokines in multiple myeloma patients: Role of chemokine (C-C motif) ligand 20.Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formationThe proapoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and is enhanced by the combination with arsenic trioxide.The anti-tumoral effect of lenalidomide is increased in vivo by hypoxia-inducible factor (HIF)-1α inhibition in myeloma cells.Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation.Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease.Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?Possible targets to treat myeloma-related osteoclastogenesis.Myeloma cells inhibit non-canonical wnt co-receptor ror2 expression in human bone marrow osteoprogenitor cells: effect of wnt5a/ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells.Role of Osteocytes in Myeloma Bone Disease: Anti-sclerostin Antibody as New Therapeutic StrategyOverexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocationsBone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patientsLow bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cellsMicrovesicles released from multiple myeloma cells are equipped with ectoenzymes belonging to canonical and non-canonical adenosinergic pathways and produce adenosine from ATP and NADThe potential of inhibiting glutamine uptake as a therapeutic target for multiple myelomaThe link between bone microenvironment and immune cells in multiple myeloma: Emerging role of CD38
P50
Q26782214-A3C0658D-64AE-45DC-B963-44E53499B578Q28082335-FFB809D8-DC9D-45AD-B955-44D0D9367AC4Q33574203-184719B0-55B9-4A01-A84E-106618BE81EDQ38232436-02726204-5D7D-4BCB-B16C-AF340439E63BQ38271428-DB5E96B5-B6BD-40B8-B7C0-B9F422609804Q38685897-55DCC9A0-CBE7-46D9-9AA4-8E99B66E2F31Q38764048-D29A450A-8273-472F-907A-1284D4B7C1B1Q38766239-70160DE8-439D-4C99-A7A9-2CB1BD299228Q38820789-C5585E19-1CCF-4F91-8BE8-65DFD41FA063Q39205798-3DD47CEA-30F7-47C3-9FB9-9A2A8C97C6A6Q39239701-A3C658D0-C0BF-4556-AAAB-FE4599F12F42Q39616165-81B0317E-1CAC-4823-8D81-0219F5557C89Q40485837-45D04145-CA6F-4D30-B9E8-755578C9983FQ41345636-7735F071-DB9C-4820-ADE7-7A13ECF2DC8FQ42846656-DBE3BE8E-335D-4B40-8550-5880A992DEC9Q42923841-EF263BB5-418D-431A-B208-9EA50351DF95Q44774590-3E0C5CC7-8038-4E93-9066-4BEF50D14426Q46410066-2C905870-7061-4CCD-81AE-15A43D340DABQ48323207-661ADE54-9D7A-452B-B2E7-16EC26B26423Q52678864-790238CF-EC65-40C2-B82C-470A55AD8578Q54301591-54ABE687-182F-4D63-9981-A6FAF7234FE4Q58566593-CBAAF645-3C6A-43BF-8046-F06374F5DBC6Q60197153-25AE1232-C041-407B-A015-F5646EC9CDBAQ60197156-F97DF67F-06F3-452E-9388-1A49E515847FQ60197167-6A21C37F-71C5-43C7-9987-EC0FC2D71D29Q61398598-AF24122B-5824-4F3A-B565-DBF48B42B176Q61398613-B632420E-1268-4686-BCC3-613313EA4449Q88493512-49C5DF08-C5D8-420C-8106-4E00CCAC4233
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Marina Bolzoni
@ast
Marina Bolzoni
@en
Marina Bolzoni
@es
Marina Bolzoni
@nl
Marina Bolzoni
@sl
type
label
Marina Bolzoni
@ast
Marina Bolzoni
@en
Marina Bolzoni
@es
Marina Bolzoni
@nl
Marina Bolzoni
@sl
prefLabel
Marina Bolzoni
@ast
Marina Bolzoni
@en
Marina Bolzoni
@es
Marina Bolzoni
@nl
Marina Bolzoni
@sl
P1053
K-4032-2016
P106
P1153
35795111900
P21
P31
P3829
P496
0000-0002-0821-8093